Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 39M | 55.7% |
| Gross Profit | 11M | 80.2% |
| Cost of Revenue | 28M | 11.1% |
| Operating expense | 65M | 8.2% |
| Net Income | -32M | 234.8% |
| EBITDA | -26M | 6.2% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 189M | 11.5% |
| Total Liabilities | 349M | 0.9% |
| Shares Outstanding | 125M | 0.5% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -19M | 49.5% |
| Cash from investing | 7.5M | 85.4% |
EPS
Financial Highlights for Karyopharm Therapeutics in Q3 '24
Karyopharm Therapeutics reported a revenue of 39M, which is a -55.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. A decline in revenue can be concerning, as it might indicate reduced sales or challenges in the market. It's important to investigate further to understand the underlying causes.
Gross Profit stood at 11M, marking a -80.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 28M, a -11.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 65M, showing a -8.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -32M, showing a -234.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -26M, showing a 6.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Karyopharm Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
